Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study

The PROHEAR Study is a placebo-controlled, randomized, double-blind, split-body trial in which participants receive ACOU085, a Kv7.4 channel activator, in one ear and a placebo in the contralateral ear. The study is currently being conducted at 13 leading German ENT university clinics and is still actively recruiting. ThePROHEAR Studyis aplacebo-controlled, randomized, double-blind, split-body trialin which participants receiveACOU085, a Kv7.4 channel activator, in one ear and a...

The PROHEAR Study is a placebo-controlled, randomized, double-blind, split-body trial in which participants receive ACOU085, a Kv7.4 channel activator, in one ear and a placebo in the contralateral ear. The study is currently being conducted at 13 leading German ENT university clinics and is still actively recruiting.

"This marks a significant milestone on Acousia's journey to offer a treatment for the prevention of permanent hearing loss caused by cisplatin," said Professor Hubert Löwenheim, Chair of the Department of Otolaryngology - Head & Neck Surgery at Tuebingen University and Scientific Supervisor of the study. "Preventing this often overlooked side effect is critical for cancer patients. Notably, all PROHEAR participants who have received ≥300 mg/m² of cisplatin to date have developed ototoxicity. This is higher than reported in most, if not all, previous studies."

The PROHEAR Study is on track to complete enrollment by the end of the second half of 2025. For more information, visit clinicaltrials.gov.

ACOU085 (INN: bimokalner) is a first-in-class, small-molecule, etiology-agnostic otoprotective drug-candidate delivered using standard transtympanic administration of a proprietary, slow-release gel formulation. Ototoxic hearing loss is a typical, severe, and permanent side effect of cisplatin treatment and is a consequence of irreversible damage to the sensory cells in the inner ear, the so-called outer hair cells (OHCs). ACOU085 modulates a biologically validated target, the KCNQ4-encoded Kv7.4 potassium channel of the OHCs, and has demonstrated significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity in preclinical models.

Contact

Tim Boelke, M.D.
[email protected]
www.acousia.com

View original content:https://www.prnewswire.co.uk/news-releases/acousia-therapeutics-reaches-50-patient-enrollment-milestone-in-phase-2-prohear-study-302440117.html